Oryzon Genomics - Key milestones and extended cash runway
Oryzon is progressing with its lead assets, iadademstat and vafidemstat, in the clinic. The ALICE study continues to generate positive readouts in...
760 Views
Oryzon Genomics - Continued positive responses in ALICE trial
Oryzon presented a 42-month update of its ongoing Phase IIa ALICE trial for the treatment of acute myeloid leukaemia (AML) in newly diagnosed...
741 Views
Oryzon Genomics - FRIDA funding and orphan drug designation
Oryzon Genomics has been awarded a $2m public grant to support its ongoing Phase Ib FRIDA clinical study. This follows recent FDA approval of its...
729 Views
Oryzon Genomics - Planning iadademstat’s path to market
Oryzon is making progress with its two epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications (both are lysine-specific...
1.1k Views
Oryzon Genomics - Large response benefit consistent in ALICE trial
On 11 June 2021, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual Congress of...
973 Views